Despite these contrasting effects, sustained IL-10 signaling has emerged as a promising strategy for cancer immunotherapy, as it effectively activates and expands tumor-specific cytotoxic CD8+ T cells while concurrently mitigating tumor-associated inflammation. The gene discussed is CD8A; the disease is neoplasm.